By Business/Source
No Data
By Product
Currency:CNY
2025/H1
Stock NameRevenueRatio
某一时间点-许可费收入245.57M76.88%
某一时间点-药品销售及特许权使用费收入67.02M20.98%
某一时间点-提供用于研发项目的货品及消耗品收入6.33M1.98%
某一段时间-许可费收入523K0.16%
By Country/Region
No Data